B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders.

“CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.” Croatian Medical Journal: “Therapies for multiple sclerosis targeting B cells.” National Multiple ...

Odronextamab is an investigational bispecific antibody that binds to CD20 expressed on the surface of B cells, and to CD3 receptor expressed on the surface of T cells. This results in local T-cell ...

Janssen has retained its rights to develop and commercialize B-cell targeting CD28 bispecific antibodies, including JNJ-9401 (PSMA x CD28) and JNJ-1493 (CD20 x CD28). "Plamotamab is a Phase 2 ...

In addition to studying T cells, the researchers identified a role for CD20 + B lymphocytes, a less commonly discussed immune cell type in melanoma. About 22% of the tumors contained these B cells ...

She noted that unlike rituximab, which targets CD20, inebilizumab targets CD19, although both medications lead to B-cell depletion. Rituximab has proven effective for MUSK–positive MG ...